1. Park HM. 123I: almost a designer radioiodine for thyroid scanning. J Nucl Med. 2002;43:77–8.
2. Park HM. Potential adverse effect of high survey dose of 131I administered prior to 131I therapy in the management of differentiated thyroid cancers. In: Schmidt H, Van Der Schoot JB, editors. Nuclear medicine: the state of the art of nuclear medicine in Europe. Stuttgart: Schattauer; 1991. p. 340–2.
3. Park HM, Perkins OW, Edmondson JW, Shnute RB, Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative dose of 131I. Thyroid. 1994;4:49–54.
4. Park HM. The stunning effect in radioiodine therapy of thyroid cancer. Nucl Med Ann. 2001: 49–67.
5. McDougall IR. 74 MBq 131I does not prevent uptake of therapeutic doses of 131I in differentiated thyroid cancer. Nucl Med Commun. 1997;18:505–12.